Article | March 31, 2023

Analysis Paralysis: Navigating Early-Phase Analytical Validation

By Dustin Lafferty, Singota Solutions

Chromatography Lab GettyImages-482759508

Significant confusion persists across the pharmaceutical/biopharmaceutical industry relevant to early-phase analytical development and validation. While several guidance documents serve as a de facto standard, distinguishing method validation requirements from suggestions, when and how to apply those guidelines often is not a straightforward task.

It is critical to establish a product/project’s analytical life cycle early and to revisit findings throughout a project. Despite working with limited information, method qualification researchers often can gather a significant amount of data on the molecule early in development, thus establishing a method that is specific, accurate, and has good linearity. Moreover, as the project progresses (usually over several years), that library of data will remain as a reference for validation. This way, drug developers can access past analyses to understand and exhibit how well the method has held up during the drug’s life cycle.

With time and experience (i.e., working with the molecule), it is possible to identify pinch points that require optimization (particularly those with significant timeline impacts). This experience also reinforces the method’s robustness because, by full validation, researchers will have prepped solutions multiple times.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma